header logo image


Page 20«..10..19202122..3040..»

Archive for the ‘Arthritis’ Category

AbbVie Submits Regulatory Application to FDA for RINVOQ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis – BioSpace

Monday, August 31st, 2020

NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie(NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.

"Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals," said Michael Severino, M.D., vice chairman and president, AbbVie. "RINVOQ has the potential to improve care by helping to provide disease control, addressing pain and improving function. We look forward to working with regulatory authorities and hope to bring this important treatment option to patients."

The applications to the FDA and EMA are supported by data from SELECT-AXIS 1, a Phase 2/3 study in which RINVOQ demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis.1 In this study, twice as many patients receiving RINVOQ (52 percent) met the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response versus placebo (26 percent) at week 14 (p<0.001).1 The safety profile of RINVOQ in ankylosing spondylitis was consistent with previously reported studies across therapeutic areas, including rheumatoid arthritis, atopic dermatitis and psoriatic arthritis, with no new significant safety risks detected.2-4

Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide.5,6 The range of symptoms pose significant physical, psychological and economic burden on individuals impacted by the disease.5,7-9

About RINVOQ (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.10-17 In August 2019, RINVOQ received U.S. FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.12-17 Use of RINVOQ in ankylosing spondylitis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)18

RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for theFull Prescribing InformationandMedication Guide. Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Rheumatology

For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie on Twitter,Facebook,Instagram,YouTubeandLinkedIn.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-301117875.html

SOURCE AbbVie

See the article here:
AbbVie Submits Regulatory Application to FDA for RINVOQ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis - BioSpace

Read More...

Global Psoriatic Arthritis Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To…

Monday, August 31st, 2020

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Therapeutics Market market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Therapeutics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Therapeutics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.

Request Covid 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.

Global Psoriatic Arthritis Therapeutics Market: Dynamics

Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.

Global Psoriatic Arthritis Therapeutics Market: Segment Analysis

Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.

Global Psoriatic Arthritis Therapeutics Market: Trends

The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

Nonsteroidal anti-inflammatory drug (NSAID)Disease-modifying antirheumatic drug (DMARD)Biologic drugEnzyme inhibitor

Segmentation by diseases type:

Asymmetric Psoriatic ArthritisSymmetric Psoriatic ArthritisDistal Interphalangeal Predominant (Dip) Psoriatic ArthritisSpondylitisArthritis Mutilans

Looking for more? Check out our repository for all available reports on Psoriatic Arthritis Therapeutics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Global Psoriatic Arthritis Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To...

Read More...

Cartilage Is Grown in the Arthritic Joints of Mice – The New York Times

Monday, August 24th, 2020

The researchers wanted to turn those awakened stem cells into cartilage. The recipe that worked was to treat the stem cells with bone morphogenetic protein, which is used to help fuse bones.

The scientists also used a drug called Avastin, which prevents the stem cells from getting a blood supply. Unlike bone and bone marrow, cartilage has no blood supply, and the drug helped stimulate the stem cells to turn into cartilage.

The investigators provided the drugs directly to the ends of bones, putting them in a gel.

The cartilage that grew in the mice not only looked like normal but lasted for four months, a quarter of the animals lifetimes. Dr. Chan and Dr. Longaker envision a time when doctors will be able to resurface arthritic joints or, even better, to treat people who are just beginning to develop arthritis, perhaps staving off the sort of damage that even joint replacements cannot fix.

If the strategy works in humans, then early treatment may be the best approach, Dr. Marx said.

Arthritis deforms joints and changes bones, he said. By the time people have hips or knees replaced, irreversible damage may be done. Legs may be bowed, bones damaged.

You cannot totally turn back the clock, Dr. Marx said. At that point, he said, adding cartilage will not fix it.

He worries, though, that orthopedists may not wait for rigorous studies the method of awakening the dormant cells is relatively simple, and the drugs required are already on the market.

Faced with a patient with aching knees, orthopedists may be tempted to say, Lets try this. You dont have much to lose, Dr. Marx noted.

Continue reading here:
Cartilage Is Grown in the Arthritic Joints of Mice - The New York Times

Read More...

Maintaining Treat-to-Target Strategies for Rheumatoid Arthritis During the COVID-19 Pandemic – Rheumatology Advisor

Monday, August 24th, 2020

Treat-to-target and safe tapering strategies should continue to be essential in the management of rheumatoid arthritis (RA) during the coronavirus disease 2019 (COVID-19) pandemic, according to a commentary published in Lancet Rheumatology.

The National Institute for Health and Care Excellence COVID-19 guidelines suggested that face-to-face patient consultations should be avoided, unless patients present with a disease flare; patients with stable disease should be treated remotely. However, the definition of stable disease may be misguided, the authors of the commentary noted. Even amid the pandemic, treat-to-target strategies should be preserved to maximize the number of patients achieving remission.

Treat-to-target refers to arthritis management that prioritizes low disease activity or remission. With treat-to-target, patients set specific management targets and undergo frequent laboratory tests and clinical examinations. If disease targets are not met, different treatment strategies are adopted. Research has suggested that up to 50% of patients can achieve remission through treat-to-target.

While focused efforts may be taken to mitigate COVID-19 risk, rheumatologists should prioritize treat-to-target for their patients. Although patients with minimal disease activity or remission may be good candidates for remote management, patients who have yet to reach their treatment goals should be considered for clinic visits.

Patients undergoing dose tapering may also require clinic visits, the authors added. Clinical examination of the joints is often necessary to detect flares. In addition, in the context of the pandemic, some patients may be self-tapering because of fears of their drugs increasing the risk for COVID-19. While early observational data has suggested that disease-modifying antirheumatic drugs do not increase risk for COVID-19, research is still ongoing. Clinicians should make every effort to monitor patients who are tapering and minimize the risk for disease flares.

Ideally, development of one-stop shop clinics may be the best way to manage RA while minimizing hospital contact. While efforts to maintain physical distancing are essential, patients with RA should not have to endure disease flares as a result.

Treat-to-target and safe tapering strategies should continue to be essential in the management of rheumatoid arthritis, regardless of new approaches that streamline the patient experience and reduce the number of hospital visits, the authors concluded.

Yeoh SA, Ehrenstein MR. Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic? Lancet Rheumatol. 2020;2(8):e454-e456.

See more here:
Maintaining Treat-to-Target Strategies for Rheumatoid Arthritis During the COVID-19 Pandemic - Rheumatology Advisor

Read More...

Arthritis pain – the best vegetable to lower your risk of joint pain and inflammation – Express

Monday, August 24th, 2020

Arthritis pain can lead to a number of debilitating symptoms that patients will want to try and avoid.

The condition can make life more difficult when carrying out simply, everyday tasks.

It's crucial that if you develop signs of arthritis, you speak to a doctor as soon as possible to try and find a treatment to relieve your pain.

One of the best ways to avoid arthritis pain is to eat more broccoli, it's been claimed.

READ MORE: Arthritis pain - common household sauce you should avoid

"Although there is no diet cure for arthritis, certain foods have been shown to fight inflammation, strengthen bones and boost the immune system," said the Arthritis Foundation of Asia.

"Adding these foods to your balanced diet may help ease the symptoms of your arthritis.

"Rich in vitamins K and C, broccoli also contains a compound called sulforaphane, which researchers have found could help prevent or slow the progression of osteoarthritis.

"Broccoli is also rich in calcium, which is known for its bone-building benefits."

You could also lower your risk of arthritis by eating more red beans, added the Arthritis Foundation.

They could lower your chances of arthritis symptoms as they're rich in fibre.

Fibre is a crucial nutrient that helps to lower the amount of C-reactive proteins in the body.

These proteins are a marker of inflammation, which have been linked to heart disease, diabetes, and even rheumatoid arthritis.

Common arthritis symptoms include joint pain, inflammation, and restricted movement.

There are two key types of arthritis in the UK; osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common type of arthritis to be diagnosed in the UK - around nine million people are believed to have osteoarthritis.

Rheumatoid arthritis, meanwhile, is an auto-immune disease that has been diagnosed in about 400,000 individuals.

Follow this link:
Arthritis pain - the best vegetable to lower your risk of joint pain and inflammation - Express

Read More...

An Overview of Psychiatric Comorbidities in Rheumatoid Arthritis – Rheumatology Advisor

Monday, August 24th, 2020

The incidence and prevalence of rheumatoid arthritis (RA), the most common autoimmune inflammatory arthritis, is increasing worldwide; in 2014, RA affected an estimated 1.28 to 1.36 million adults.1 A growing body of research has indicated that compared with patients without RA, those with RA are disproportionately affected by psychiatric disorders, particularly anxiety and depression.2,3 Psychiatric disorders in patients with RA not only affect functioning and quality of life, but they have been associated with poorer RA outcomes, including a greater frequency of flares, lower odds of achieving remission, and increased mortality.4

Psychiatric comorbidities in RA lead to higher rates of healthcare utilization. In a retrospective cohort study by Carol Hitchon, MD MSc, clinician scientist at the University of Manitoba in Winnipeg, Canada, and colleagues,5 an analysis of health records of 12,984 patients with RA and 64,510 matched control participants for the period between 2006 and 2016 showed that patients with RA with vs without comorbid psychiatric disorders (depression, anxiety, bipolar disorder, or schizophrenia) received more types of medications, had more ambulatory physician visits and hospitalizations, and greater length of hospital stays. Investigators concluded that managing psychiatric comorbidities effectively may reduce utilization among patients with RA.

We spoke with Dr Hitchon who suggested that the presence of psychiatric disorders can complicate treatment decisions and subsequent outcomes. We know that psychiatric comorbidity [affects] how people experience pain and this may or may not be associated with joint inflammation, she added. This type of pain may be treated differently than if the pain is due to joint inflammation. Psychiatric disorders can also complicate the assessment of RA activity, since low mood or depression can influence the patient-reported components of standardized instruments such as disease activity score in 28 joints.6

Depression, the most common psychiatric comorbidity of RA, has been estimated to occur in 9.5% to 41.5% of patients with RA.2,7 A recent meta-analysis concluded that 16.8% of patients with RA had comorbid major depressive disorder (MDD), based on pooled estimates from studies that identified depression with psychiatric interviews, the gold standard for diagnosis.7 The reasons for the prevalence of depression in patients with RA typically include the adverse effects that chronic pain, fatigue, and functional limitations have on social roles and quality of life.4

We also spoke with Melissa Withers, PhD, MHS of the USC Institute on Inequalities in Global Health at the University of Southern California Keck School of Medicine, who noted that the pain and limitations associated with RA can negatively affect many aspects of patients lives. They may not be able to participate in the things that used to bring them joy, like hobbies, social interactions, or a job. Patients are especially at risk for depression and anxiety when they are first diagnosed with RA. You can imagine they hear that they are facing a debilitating, degenerative, long-term illness. So it can be very upsetting. It brings a lot of fear of what their futures will be like.

Shared inflammatory pathways are also widely believed play a role in the frequent co-occurrence of depression and RA. Studies have shown that proinflammatory cytokines implicated in RA, such as tumor necrosis factor (TNF) , interleukin (IL)-6 and IL-1, are overexpressed in patients with depression compared with healthy control participants.4 In addition to causing chronic joint inflammation and damage to the cartilage and bone, excessive levels of these cytokines may contribute to depression by having detrimental effects on neuroendocrine function, neurotransmitter metabolism, and brain structures. Increased serum and/or plasma concentrations of C-reactive protein, often seen in RA populations, are also present in patients with depression or anxiety.6

An analysis of audio recordings taken at patient visits for RA showed that rheumatologists rarely brought up the topic of depression, even among patients whose depressive symptoms were moderate to severe.8 Dr Withers recommended that rheumatologists incorporate depression identification and management into patient care plans, especially since patients may not know that a rheumatology visit is an appropriate time to bring up mental health issues. It is critical to screen patients regularly for depression and other disorders and to follow those with scores that suggest mild depression to determine if the depression worsens over time, she said. If the patient scores indicate depression or a psychiatric disorder, the rheumatologist can then refer them for consultation with a mental health professional.

Lekeisha Sumner, PhD, ABPP, a licensed clinical psychologist with a board certification in clinical health psychology and author of several papers on the psychosocial aspects of rheumatologic diseases, stated that depression and anxiety are grossly underdiagnosed and treated in rheumatologic diseases despite their high prevalence. The provider-patient relationship is key in health outcomes and especially important when discussing sensitive topics that have historically been stigmatized, she advised. Leveraging rapport with your patient to ask about how their emotional strain presents at each visit invites them to give voice to the often-silent suffering that they commonly experience. Keep in mind that some of your patients will likely have alexithymia, which not only complicates their recovery but makes it more difficult for them to identify and process their emotions. Dr Sumner recommended that rheumatologists use simple screening tools such as the Generalized Anxiety Disorder and Patient Health Questionnaire to assess mental health.

Conceptualizing symptoms of anxiety and depression as par for the course in RA conditions is ill-advised as they contribute to increased burden on the patient, diminishes overall functioning, increased pain sensitivity, affects long-term disease activity, remission, response to treatment, and quality of life, Dr Sumner noted. Recognize that your patient has likely experienced difficulties with sexual functioning, ability to earn a living and engage in daily activities with ease, resulting in shifts in identity and confidence to effectively self-manage their condition. Targeting immunologic alterations will help alleviate psychiatric distress, along with using a multidisciplinary approach to care that includes mental health professions are all key to disease management and promoting adaptive adjustment and coping.

The rest is here:
An Overview of Psychiatric Comorbidities in Rheumatoid Arthritis - Rheumatology Advisor

Read More...

Covid-19 and arthritis: Why people with joint pain should not delay treatment – The Indian Express

Monday, August 24th, 2020

By: Lifestyle Desk | New Delhi | Updated: August 22, 2020 2:26:34 pmPeople who suffer from long standing arthritis of the joints find it difficult to move andwalk around because of pain. (Photo: Getty Images/Thinkstock)

Covid-19 pandemic has taught us the importance of being fit. It is a well-known fact that a healthy mind lives in a healthy body. Certain medical conditions like diabetes, obesity and hypertension need to be well controlled to have better immunity against infections.

People who are suffering from long-standing arthritis of the joints are not able to move and walk around because of pain and disability in their joints. This can lead to uncontrolled diabetes, hypertension, and weight gain because of less calorie expenditure. This can, in turn, weaken the bones and muscles of the limbs, causing a disease called osteoporosis. This complicates the whole situation because now these people are not only just suffering from arthritis but also osteoporosis and weak muscles. This leads to increased fragility of the bone and also instability while walking. These patients have an increased tendency to fall and we are witnessing many such patients with fractures around the hip and leg bones, Dr Subhash Jangid, director and unit head, Fortis bone and joint institute, Fortis Memorial Research Institute, Gurugram told indianexpress.com.

If someone is not able to move because of weak bones and arthritis, they should get themselves treated by medication or by surgery. That is because, if they get COVID-19 infection in such a situation, they may face a tough time recovering because of weak muscles (including chest muscles) and poor immunity. Taking multivitamins and other healthy foods are not just enough to boost immunity. Health experts have repeatedly emphasised on exercising every day, maybe just a brisk walk for 30 min every day.

So, if you are suffering from hip and knee arthritis, dont delay the surgery and prolong the suffering as it is a vicious cycle that will further cause deterioration in your health. We have to take precautions and stop fearing the pandemic. Precautions are the most important thing which can save us from this illness, Dr Jangid added.

Read| Have arthritis? Some of these exercises can help

Delaying your health needs will take a toll on the recovery as well and the results may be compromised. We are seeing a lot of patients with advanced diseases owing to the delay in surgery now that they are scared to step out. Your health and immunity are the only saviour against COVID-19 and we need to focus on the same, the doctor further said.

The biggest myth is that the hospitals are COVID-19 hot spots. If hospitals would have been hot spots, almost all medical staff would have been infected by now. But that is not what we are seeing all over the world. Actually, coronavirus is everywhere and the hospitals are one of the safest places because the guards against the virus are always on. People are getting the infection from the grocery stores and markets rather than from the hospitals. Everyone remains safe if they take precautions. And in hospitals, people take maximum precautions, Dr Jangid remarked.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

The Indian Express (P) Ltd

Go here to read the rest:
Covid-19 and arthritis: Why people with joint pain should not delay treatment - The Indian Express

Read More...

Comparing the Effectiveness of Biologic Agents in the Treatment of Rheumatoid Arthritis – Rheumatology Advisor

Monday, August 24th, 2020

The use of disease-modifying antirheumatic drugs (DMARDs) and the adoption of an early and aggressive treatment strategy have transformed the outcomes of patients with rheumatoid arthritis (RA). These immunosuppressive and immunomodulatory agents are essential to the comprehensive RA treatment strategy, with an objective of achieving disease remission or sustained minimal disease activity, to prevent radiographic progression.1

The DMARDs currently available are broadly categorized as conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs). Conventional synthetic DMARDs typically include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and are generally used in the first-line setting.2 Several bDMARDs are approved for RA in 6 therapeutic classes, including tumor necrosis factor inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab); T-cell costimulatory blocking agent (abatacept); B-cell depleting agents (rituximab); interleukin-1 receptor antagonists (anakinra); interleukin(IL)-6 inhibitors (tocilizumab and sarilumab); and Janus kinase inhibitors (JAK; tofacitinib, baricitinib, and upadacitinib).3 Biosimilars, a highly similar copy of the original approved biologic agent, with no clinically meaningful differences in safety, purity, and potency, has expanded the options of bDMARDs.4 In general, bDMARDs are prescribed after the failure of first-line csDMARD therapy.

The most commonly used csDMARD in the first-line setting is methotrexate. When RA progresses despite treatment with csDMARDs, a bDMARD may be introduced as monotherapy, typically in combination with a csDMARD, such as methotrexate. In cases of disease progression, despite treatment with methotrexate and bDMARDs, clinicians are faced with an increasingly challenging choice of treatment selection to achieve optimal disease management. Over time, 2 key questions have emerged: the comparative effectiveness of bDMARD monotherapy vs the combination of a bDMARD with methotrexate, and the comparative effectiveness of the available bDMARD either as monotherapy or in combination with methotrexate. The importance of these questions may be related to treatment efficacy and safety, given the diverse RA patient population among whom approximately one-third are treated with bDMARD monotherapy, primarily because of intolerance or noncompliance with methotrexate.5

The comparative effectiveness of bDMARD vs methotrexate monotherapy has been addressed in several studies. Overall, the superiority of bDMARD vs methotrexate monotherapy has been established for all 6 classes of bDMARDs, particularly in the setting of disease progression with methotrexate.6-9

With respect to the comparative effectiveness of bDMARD monotherapy vs combination with methotrexate, available studies have shown that some bDMARDs were more efficacious in combination with methotrexate, others as efficacious as either monotherapy or in combination, and the evidence for other DMARDs were less clear.

Specifically, the superiority of the efficacy of bDMARDs in combination with methotrexate compared to bDMARD monotherapy has been evident for tumor necrosis factor inhibitors (TNFis), but not non-TNFis.5,8 Both abatacept and tocilizumab have showed effectiveness whether combined with methotrexate or used as monotherapy.5,8,10 The effectiveness of rituximab as monotherapy compared to combination with methotrexate has been less clear, with some studies reporting superior efficacy as a combination,11-13 although the effectiveness either as monotherapy or in combination with methotrexate has also been reported.14 The use of tofacitinib in RA has been inconclusive because of lack of available data.5,15 Taken together, the evidence suggests that the currently available bDMARDs vs methotrexate monotherapy achieve greater control of disease activity. However, the combination of a bDMARD with methotrexate may be more efficacious than bDMARD monotherapy for anti-TNF agents, comparable for tocilizumab and abatacept, and inconclusive for rituximab, tofacitinib, and anakinra because of paucity of studies and data.

While it has been established that bDMARDs vs methotrexate may be more efficacious in disease control, the choice of available bDMARDs can be challenging because of the lack of head-to-head comparative studies and the limited data for use of these agents. The majority of the studies that have evaluated the comparative effectiveness of bDMARDs have concluded that anakinra may be the least efficacious.16 Furthermore, the American College of Rheumatology (ACR) response was found to be higher with tocilizumab compared to a TNFi or the JAK inhibitor tofacitinib.5 Among the TNFi agents, etanercept has been reported to be the most efficacious and infliximab the least.16,17 In combination with methotrexate, excluding anakinra, available data suggest comparable efficacy across the bDMARDs evaluated.10,18

A meaningful comparative effectiveness analysis of bDMARDs has been challenged by several limitations that question the accuracy of the comparisons.3 In many cases, there are variations in study design and clinical end points. Furthermore, available data may not be comparable for all agents; for example, there is fewer data for the newer approved agents such as the JAK inhibitors. Data has typically included heterogeneous, selected patient populations, with outdated definitions of clinical end points of clinical remission and low disease activity. Furthermore, in the absence of head-to-head studies, an indirect comparison of trial findings has often resulted in inconclusive analyses challenging clinical decision-making.

A recent systematic review and network meta-analysis by Janke et al provides a more rigorous comparative effectiveness analysis of the approved bDMARDs, using a method that included data from clinical study reports and reanalyses from individual patient data on key outcomes for RA, adopting the current definitions of clinical end points.3 This approach enabled a more homogeneous patient population for comparative analysis. The 34 studies that met the criteria for comparative effectiveness analyses included 10,869 patients and investigated 8 different biologic agents in combination with methotrexate (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab, anakinra, abatacept, and tocilizumab). However, the analysis did not include rituximab, or the more recently approved agents such as sarilumab, tofacitinib, baricitinib, and upadacitinib. Overall, as reported in previous studies, there were few statistically significant differences between the bDMARDs in combination with methotrexate in terms of benefits and harms.

Researchers found that anakinra was the least efficacious in clinical remission or low disease activity3; compared to anakinra, adalimumab, certolizumab pegol, and golimumab had statistically significant advantages for RA remission, and abatacept, adalimumab, infliximab, and tocilizumab were found to have statistically significant advantages for low disease activity.3 Regarding safety, certolizumab pegol had a higher risk for serious adverse events (compared to abatacept, adalimumab, anakinra, etanercept, and infliximab) and infections (compared to abatacept, anakinra, etanercept, golimumab, tocilizumab, and infliximab). The risk for serious infections was higher with infliximab compared to golimumab and tocilizumab. The discontinuation rate due to adverse events was higher for anakinra compared to abatacept, adalimumab, etanercept and infliximab, and higher for abatacept compared to tocilizumab.3 Despite the rigorous methodology of this study, the authors acknowledged the limited data for long-term direct comparisons between the bDMARDs, with a recommendation for routine availability of individual patient data.

Although the expansion of bDMARDs provides improved treatment options, selecting treatment for the optimal disease management has been challenging because of the limited robust comparative effectiveness studies available.

The recent rigorous study by Janke and colleagues suggest a small but statistically significant differences in disease remission, and serious adverse events between the biologic agents. From a clinical decision standpoint, it is important to individualize treatment, taking into consideration disease activity, comorbidities, and patient treatment preferences, while weighing the significance of the differences between the bDMARDs for disease management and outcomes.

Original post:
Comparing the Effectiveness of Biologic Agents in the Treatment of Rheumatoid Arthritis - Rheumatology Advisor

Read More...

Rethinking Mental Illness: A Response to Inflammation – PRNewswire

Monday, August 24th, 2020

ENCINO, Calif., Aug. 24, 2020 /PRNewswire/ -- Mounting evidence is suggesting that the onset of mental illness might be due more to the presence of inflammation of the brain than just being a random or spontaneous condition. Chronic stress, traumatic and non-traumatic brain injuries and auto-immune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Grave's and Hashimoto's diseases, and even Crohn's disease are known to precipitate inflammation and be associated with depression.

Common to each of these conditions is the production of a group of inflammatory chemicals produced by our immune system and called Cytokines (IL-1, IL-6, and TNF-alpha). These same chemicals are responsible for the lung and neurological damage associated with coronavirus (COVID-19). Studies have demonstrated in patients with auto-immune Psoriatic arthritis that when they are treated with a medication (etanercept) that blocks the inflammatory cytokine TNF-alpha, aside from improvement in the arthritis, there is a significant reduction in their depression.

This neuroinflammatory hypothesis for depression and other psychiatric illnesses explains substantially more than prior models, including why emergent data shows that when analgesics, anti-inflammatory medication, hormonal replenishment, pro-neurogenic, and pro-neurotrophic treatments are used, there are beneficial effects on depression.

The brain is contained within the skull and is surrounded by cerebrospinal fluid (CSF), whose composition is derived from lifestyle choices. Nutrition, water, drugs, alcohol, medication, and traumas all influence the quality of this CSF.When the CSF is healthy, the brain has more resiliency when challenged, but when unhealthy, the changes in its chemical make-up can precipitate cognitive and emotional illnesses. The Millennium Health Centers has been working since 2004 to correct unhealthy changes to the CSF and to influence how the brain can repair after trauma.

Read some of the science at: https://tbihelpnow.org/the-science

About Dr. Mark L. Gordon

Dr. Mark L. Gordon is the founder and medical director of Millennium Health Centers, Inc. in Encino, California. In 2015, Dr. Gordon released the book, "Traumatic Brain Injury - A Clinical Approach to Diagnosis and Treatment" that presents the science and his experience treating all precipitating causes of traumatic brain injury in both active military, veteran, sports, and civilian populations. Dr. Gordon has also joined with the Warrior Angels Foundation, a 501(c)(3) charitable organization founded by veterans Andrew and Adam Marr to provide medical services to members of the armed forces both active duty and veterans. For more information, visit TBIHelpNow.org.

About Millennium Health Centers, Inc

Since 2004, the Millennium Health Centers, Inc., under the direction of Dr. Mark L. Gordon, has worked to develop a diagnostic bio-marker panel and personalized treatment protocols for both traumatic and non-traumatic brain injuries associated with neuropsychiatric symptoms.

In 2015, the Millennium Health Centers, Inc. developed a neuro-regenerative program that involves the assessment and treatment of both traumatic and non-traumatic brain injury symptoms which may include depression, anxiety, lost libido, insomnia, migraines, obsessive-compulsive disorders, bipolar disorder, cognitive disorders, Parkinson's, and dementia conditions. Many of these can present years after the initial insult(s) which are frequently never considered.

Media Contact

Mark L. Gordon, M.D., Founder and Medical Director

[emailprotected]

SOURCE Millennium Health Centers, Inc

Read more from the original source:
Rethinking Mental Illness: A Response to Inflammation - PRNewswire

Read More...

Sexual Dimorphism of Systemic Juvenile Idiopathic Arthritis Linked to Immature Neutrophil Signature – Rheumatology Advisor

Monday, August 24th, 2020

Compared with male patients, female patients with systemic juvenile idiopathic arthritis (JIA) have higher levels of genes related to circulating immature neutrophils, with these genes being associated with response to treatment, according to study results published in Journal of Leukocyte Biology.

The prevalence of systemic JIA has been estimated to be 3 times higher in female than male patients; female patients were also found to have lower rates of response to treatment.

The aim of the current study was to characterize blood gene signatures of 3 cohorts of male and female patients with JIA and assess the effect of sex on the whole blood transcriptomes of patients.

Researchers included clinical metadata from 451 patients and analyzed whole blood transcriptomic data of those with and without systemic JIA. They performed differential expression analyses for male and female patients, separately.

The number of differentially expressed genes was similar in male and female patients with systemic JIA compared with sex-matched control participants. However, because most differentially expressed genes were not shared between males and female patients, researchers suggested sexual dimorphism of systemic JIA at a molecular level.

There were a total of 44 genes whose fold-change expression was much higher in female vs male patients with systemic JIA compared with control participants. Of these genes, 18 were associated with neutrophil functions (adjusted P <.0001). In comparison, a total of 47 genes were highly induced in male patients with systemic JIA. Several of the genes associated with neutrophil functions were specific for female patients and were not expressed in male patients with systemic JIA.

Among the 44 genes in systemic JIA female-specific signature, 9 were highly expressed in neutrophil progenitor cells, suggesting that circulating immature neutrophils may be more positively activated or in higher numbers in female vs male patients with systemic JIA.

The potential effect of patient sex on levels of immature neutrophils in response to treatment with anti-interleukin-1 (anakinra) was assessed by comparing the expression of band neutrophils signature in female and male patients with systemic JIA after treatment. The data suggest that while in male patients there was no change in band neutrophils signature, in female patients compared with healthy control participants, the expression of band neutrophils was higher; expression of band neutrophils was even higher after the first month of treatment and only went down after 6 months of treatment.

Data also suggest that that this immature neutrophil signature is sexually dimorphic across the human lifespan and in adults with rheumatoid arthritis and asthma.

These results suggest that neutrophil maturation is sexually dimorphic in rheumatic inflammation, and that this may impact disease progression and treatment, the researchers concluded.

Prada-Medina CA, Peron JPS, Nakaya HI. Immature neutrophil signature associated with the sexual dimorphism of systemic juvenile idiopathic arthritis. Published online August 13, 2020. J Leukoc Biol. doi:10.1002/JLB.6MA0720-015RR

Read more:
Sexual Dimorphism of Systemic Juvenile Idiopathic Arthritis Linked to Immature Neutrophil Signature - Rheumatology Advisor

Read More...

Psoriatic Arthritis Treatment Market 2020 Global Industry Analysis By Size, Trends, Share, With Regional Forecast To 2026 – The Daily Chronicle

Monday, August 24th, 2020

Fortune Business Insights Published Psoriatic Arthritis Treatment Market Report. The Psoriatic Arthritis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

An Overview of the Impact of COVID-19 on Psoriatic Arthritis Treatment Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Market Highlights:

The report offers insights into the ongoing Psoriatic Arthritis Treatment market trends. The report provides forecast values for the market for the period of 2019-2026. It highlights leading companies in the market and discusses the strategies that these companies have adopted in recent years. The competitive landscape scenario has been discussed in detail. Factual figures have been evaluated through trusted sources. Other forecast values have been gathered through interviews and opinions of experienced market research professionals.

Global Continuous Renal Replacement market 2020 research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Global Psoriatic Arthritis Treatment market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The report also focuses on global major leading industry players of Global Psoriatic Arthritis Treatment market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Global Psoriatic Arthritis Treatment Market Share and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Psoriatic Arthritis Treatment Market Forecast (2020-2026):

Psoriatic Arthritis Treatment Market Include the Following Manufacturers Based on Psoriatic Arthritis Treatment Sales, Revenue, Price and Gross Margin. The analysis of the Psoriatic Arthritis Treatment Market is a thorough study that offers a select combination of skillful market realities. The study shows changing trends of the market as well as the size of each separate segment in this market. Various product types and application are shown below.

Competition landscape of the global Psoriatic Arthritis Treatment market is brimming with private, commercial and government organizations, progressing towards introducing innovations in the field of life sciences with research & development activities. Established companies in the Psoriatic Arthritis Treatment market are exploring opportunities in developing nations like India to enhance their revenue gains.

Psoriatic Arthritis Treatment Market 2020 global industry research report is a professional and in-depth study on the Psoriatic Arthritis Treatment market trends, share, size, growth, as well as industry analysis. Furthermore, market size, the revenue shares of each segment and its sub-segments, as well as forecast figures are also covered in this report. Psoriatic Arthritis Treatment Market Forecast 2025 report study provides key statistics on the market status of the Psoriatic Arthritis Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Regions Covered in Psoriatic Arthritis Treatment Market Report:

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Psoriatic Arthritis Treatment by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Table of Contents:

1 Market Overview

1.1 Psoriatic Arthritis Treatment Introduction

1.2 Market Analysis by Type

2 Manufacturers Profiles

3 Sales, Revenue and Market Share by Manufacturer

3.1 Global Psoriatic Arthritis Treatment Sales and Market Share by Manufacturer (2018-2019)

3.2 Global Psoriatic Arthritis Treatment Revenue and Market Share by Manufacturer (2018-2019)

3.3 Market Concentration Rate

3.4 Market Competition Trend

Continued

Related News:

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

Supreme Headquarters,

Pune Banglore Highway, Baner, Pune,

Maharashtra 411045, India

Email: [emailprotected]

See the article here:
Psoriatic Arthritis Treatment Market 2020 Global Industry Analysis By Size, Trends, Share, With Regional Forecast To 2026 - The Daily Chronicle

Read More...

Anti-Inflammatory Spices to Cook With Every Day – LIVEKINDLY

Monday, August 24th, 2020

Suffering from stiff, sore joints? You just might find relief in the form of plants. Studies have identified a number of spices that have anti-inflammatory benefits, and when eaten every day, can have an even greater impact on improving your overall health.

A 2018 study published in the Journal of Translational Medicine shows spices can help to reduce inflammation, which leads to joint pain and swelling.

They may also help prevent certain cancers and other chronic diseases like arthritis, asthma, and gastrointestinal disorders. Epidemiological studies show the rate of certain cancers in countries like Indiawhere spices are consumed on a daily basisare lower than in Western countries like the U.S., where spices are consumed far less.

Inflammation is the bodys natural response to irritants or things that may harm it. These include pathogens, stimuli, toxins, infections, and injuries.

But Dr. Robert H. Shmerling, the medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School, says not all inflammation is bad. People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy, he wrote in Harvard Health Publishing.

Inflammation occurs in two main stages: acute and chronic. Shmerling explained that acute inflammation occurs when the bodys immune system releases white blood cells to protect the body. The body can experience swelling, redness, and painful joints as a result.

Acute inflammation is how your body fights infections and helps speed up the healing process, he said.

On the other hand, chronic inflammation occurs when injuries or infections persist and the body continues to produce white blood cells, which can attack the bodys healthy organs and tissues.

According to the 2018 study, chronic inflammation may lead to chronic diseases, such as cancer, arthritis, and diabetes. But researchers say spices can help to mitigate this. Congregate evidence suggests that a diet rich in plant-based agents including spices has the ability to prevent most of the chronic diseases, the studys authors wrote.

Kim Larson, a registered dietitian nutritionist certified by the National Board for Health and Wellness Coaching, agrees that spices have tremendous anti-inflammatory properties. I think people are often surprised at what a great anti-inflammatory source spices can be, she told Arthritis.org.

She continued: The more anti-inflammatory foods and spices you eat, the more you are tamping down on chronic inflammation.

A fan of yellow curry? You may already be reaping the benefits of turmeric. The spice is common in Indian and other South Asian cuisines. Studies have shown the yellow spices active chemical, called curcumin, has a number of anti-inflammatory benefits.

A 2017 study reviewed curcumins effects on human health. It found that curcumin can help to manage certain inflammatory conditions like arthritis and anxiety. It may also help to manage exercise-induced inflammation, such as sore muscles.

A similar study, released last year and published in Biomed Central, found curcumin was equally effective at relieving the symptoms of osteoarthritis as the anti-inflammatory drug NSAID diclofenac. Of those studied, 94 percent of those taking curcumin and 97 percent of those taking diclofenac reported at least a 50 percent improvement in symptoms.

Another popular spice used in Indian, Mexican, and South American dishescumin seed is a fruit of the flowering plant, which is native to India, China, the Middle East, and the eastern Mediterranean region.

Similar to turmeric, studies show the active ingredients in cumin seeds have antiseptic and anti-inflammatory effects.

If you suffer from painful, sore jointsyou just may want to opt for a little fresh ginger in your afternoon cup of tea.

A 2013 study published in the U.S. National Library of Medicine found ginger to have a number of anti-oxidative and anti-inflammatory effects on human health. The anticancer potential of ginger is well documented and its functional ingredients like gingerols, shogaol, and paradols are the valuable ingredients which can prevent various cancers, the studys authors wrote.

In addition to cancer, researchers also found that ginger has the potential to treat a number of ailments. These include degenerative disorders like arthritis, digestive health issues like indigestion and constipation, and cardiovascular disorders like hypertension.

If you can handle the heat, cayenne peppers are another terrific anti-inflammatory spice to cook with.

Cayenne and other hot chili peppers contain capsaicinoids an active compound called capsaicinoids, which have anti-inflammatory properties. Similar to turmeric, studies show capsaicin produces comparable anti-inflammatory effects as diclofenac.

If youre not already cooking with garlic, you definitely should be. Although the spice has a fairly strong taste and smell, studies have shown it has numerous health benefitsincluding reducing inflammation in the body.

Bad breath aside, garlic contains an anti-inflammatory compound called diallyl disulfide. The compound helps to minimize the effects of inflammation-causing cytokines, which are small proteins responsible for cell signaling.

If cayenne pepper is too spicy, opt for black pepper. The common cooking spice still packs a powerful anti-inflammatory punch and also has antibacterial and antioxidant benefits.

Known as the King of Spices, black pepper contains piperine, which studies show has anti-inflammatory and anti-arthritic properties.

Youll want to sprinkle extra cinnamon atop your toast and morning latte because the popular dessert spice is known to also help alleviate some symptoms caused by inflammation.

The cinnamon contains cinnamaldehydea compound that gives the sweet spice its flavor and smell. The compound has been shown to help prevent blood platelets from sticking together, as well as ease swelling.

When consumed on a regular basis, these seven spices may help to reduce the symptoms associated with inflammation for improved overall health.

Go here to read the rest:
Anti-Inflammatory Spices to Cook With Every Day - LIVEKINDLY

Read More...

What Science Knows About Fibromyalgia, a Painful Illness That is Often Invisible – Discover Magazine

Monday, August 24th, 2020

During my first month with fibromyalgia, I lived in a daze. Bizarre new sensations were plaguing my body that I had never felt before. What, for example, were my fluttering heart and inexplicable new intolerance to the heat trying to tell me? Or the seismic waves of pain racking my body, my sudden apathy to sex and my new inability to digest previously loved foods? I initially attributed it all to the heat in New Delhi and carried on, hoping for the best.

But the rapid worsening of symptoms made it hard to ignore them. In the absence of an answer, I turned to the web, where WebMD suggested lung cancer and allergies with cheerful alacrity. I cheated on one doctor with the next, experimenting with ones test and then anothers treatment, like physicians roulette, but nothing worked. And then, one day, a wizened rheumatologist squeezed mounds of my flesh between the tips of his fingers and hmmed and ahhed before ruling me a survivor of the chronic pain syndrome, fibromyalgia.

As it turns out, Im one in a vast pool of fibromyalgia syndrome (FMS) sufferers. The condition affects 10 million people just in the U.S., and an estimated 80 to 90 percent of all diagnosed patients in the world are women. But the jurys been out for decades on what causes it. Conjectures vary from family history of rheumatoid illnesses to childhood trauma and severe physical or emotional stress. To make matters more difficult, a general practitioner can't confirm or rule the condition out through bloodwork or an X-ray. Widespread pain for over three months the key criteria for a fibromyalgia diagnosis could also point to other conditions, all of which need to be laboriously ruled out before a patient receives the diagnosis.

Severity of symptoms vary, ranging from a tolerable, dull pain to discomfort so severe that its nearly impossible to get out of bed. Lady Gaga, for example, tells in the Netflix documentary Five Foot Two, how she powers through on bad pain days with a bevy of physicians at her side, pumping her body with corticosteroids before performances. But it can take years to get where she is. Labyrinthine corridors of pain management clinics, at any given time, teem with FMS sufferers who hunt for solidarity amongst strangers as they ask one another, Do you also? and what do you do for the? and Im tired of being disbelieved.

Yet, even as FMS continues to be a mystery to medical practitioners around the world, recent research has slowly started to shed light on some of its major symptoms offering new hope to the millions who suffer from it.

Amir Minerbi, a specialized pain physician at the Alan Edwards Pain Management Unit at McGill University, says he treats many individuals affected by fibromyalgia. And his patients are frustrated.

They share how long it takes to get diagnosed, how ineffective many of our treatment modalities are, how difficult it is for others to understand what they are going through friends, family and even medical personnel, Minerbi says.

In a June 2019 study in the journal Pain, Minerbi and colleagues found that compared to healthy individuals, patients with fibromyalgia had a different composition of gut microbes. We used this correlation to teach a computer to classify patients from controls, and reached reasonably good accuracy, says Minerbi.

While the demonstration so far doesnt confirm that the absence or presence of certain bacteria causes fibromyalgia, the team is keen to build on the study to search for a causal relationship. Minerbi says that the hope is to be able not only to make faster, more accurate diagnoses of fibromyalgia, but also to treat it by manipulating the microbiome.

This improved understanding could one day lead to the creation of new diagnostic tools, the researchers concluded in their study.

Gut disturbances arent the only symptoms that have received recent attention in relation to FMS. This year, researchers also studied the chronic conditions overlap with mental health.

In June 2020, a study in the journal Arthritis Care & Research examined the connection between self-harm and severe rheumatological conditions. The group of scientists, led by epidemiologist James Prior at Keele University in the UK found that, of all the conditions studied, self-harm was most prevalent among patients with fibromyalgia even more than conditions like rheumatoid arthritis or osteoarthritis.

Fibromyalgia sufferers were also found to have greater incidence of depression and mental health issues than patients with the other arthritic conditions studied. Prior says the link between fibromyalgia and depression was unearthed out of medical records of patients, who have their conditions listed on the UKs primary care database as soon as they visit a primary care provider. This makes sense, given that anti-depressants are a recommended treatment for fibromyalgia symptoms.

We were certainly pleased that our work has highlighted that healthcare professionals need to be aware of the impact that this invisible condition has on the mental health of patients with rheumatological conditions, especially fibromyalgia, says Prior.

Mental health is indeed an important factor to look out for in FMS, since it can both cause and be the cause of other symptoms. Sexual dysfunction, for instance, is an FMS symptom that rarely gets attention even though it, too, can lead to mental health issues. Fortunately, recent research has been shedding light on fibromyalgia's effects on the reproductive system, as well.

Several studies over the years have recorded the loss of libido and sexual dysfunction among patients with fibromyalgia. What should comfort both FMS patientsand their partners, though, is the understanding developing in this arena. Research is examining how women on anti-depressants can face loss of arousal, vaginal lubrication and apathy to sex and how their long-term sexual partners are working with them to find a solution.

A study published in November 2019 in PLOS ONE, led by Patricia Romero-Alcal at the University of Almeria in Spain, investigated the changing realities of couples living with fibromyalgia. Although limited in that it looked only at heterosexual relationships, the study is promising in its recognition of sexuality as an important aspect of FMS.

Other studies have found a definite association between female sexual dysfunction and fibromyalgia as well as a possible relationship between depression and sexual dysfunction in premenopausal women with the condition. The one thing common among them is all, is the evidence for patients need for sexological support.

While research is ongoing, a medical breakthrough to treat FMS is still some distance away. Science is still no closer to explaining is what actually causes fibromyalgia and how one can map its probable development in the next generation.

Besides concrete data, what FMS sufferers need in general is empathy. Millions of FMSsufferers around the world currently struggle with validation, considering their condition is still widely considered an invisible illness. Coupled with the disquieting feeling of never knowing which symptom will hit next, fibromyalgia can be a hard burden to bear. Perhaps now, as we inch closer and closer to effectively diagnosing and treating fibromyalgia, those in-between years of waiting will be cut significantly shorter.

Heres hoping.

Go here to read the rest:
What Science Knows About Fibromyalgia, a Painful Illness That is Often Invisible - Discover Magazine

Read More...

HEALTH MATTERS: Exercise benefits in the time of COVID-19 – newportri.com

Monday, August 24th, 2020

"Motion is medicine" is a saying to live by, and it may be more important than ever during the COVID-19 crisis.

Michael Mason, DO, is an orthopedic surgeon with Newport Orthopedics, a Lifespan Physician Group practice. We asked him to explain why its so vital to stay active.

***

Exercise is valuable self-care practice at all times, but especially now, during the era of COVID-19.

Regular exercise provides enormous orthopedic and general health benefits, including protection against diabetes, obesity, high blood pressure, osteoporosis and fractures, heart disease, and more. Some of these conditions put people at higher risk of serious COVID-19 illness.

The pandemic certainly has heightened our stress levels. Exercise helps by causing our body to release endorphins, which lift our mood. Getting outdoors in the sun spurs our skin cells production of vitamin D, which is good for bones, muscles, and teeth.

Besides maintaining your bodys strength and endurance, exercise helps your joints function better. Cartilage, which cushions the ends of the bones in our joints, relies on synovial fluid, not blood, for its nutrients. Exercise compresses the joints, forcing more of this nutrient-rich fluid into the cartilage, helping it stay lubricated and healthy.

Some kinds of exercise lend themselves to social distancing, such as tennis, golfing, bicycling, swimming, and walking or hiking.

A combination of exercises flexibility, aerobic and strengthening is great for everyone, but especially for people with arthritis. Swimming is particularly beneficial, and according to the Centers for Disease Control, theres no evidence that SARS-CoV-2, the virus that causes COVID-19, can spread to people through water. The CDC advises that you not wear a mask while in the water, because its harder to breathe if it gets wet. Be sure to stay at least 6 feet away from others, unless they are from the same household.

In summer, I like to sail, but I also enjoy taking walks and playing outdoors with my dog. Aquidneck Island has plenty of options for walkers who want to enjoy nature and beautiful scenery, which uplifting for your spirits.

If youre still not comfortable being near others, or have concerns because youre in a high-risk group, you can exercise at home with online fitness classes. There are many options to choose from.

Without exercise, arthritic joints become more stiff and painful, and bones become brittle and susceptible to fractures. Studies have shown that exercising may help patients with mild to moderate arthritis delay hip replacement surgery.

When joint replacement cant be put off any longer, todays patients benefit from major advances such as reduced surgery time, shorter hospital stays, and quicker recovery time. Patients regain a greater range of motion than in years past, and the joint implants last much longer.

Newport Hospital is unique in Rhode Island in using Radlink GPS imaging technology during joint replacement procedures. This technology allows the surgeon to analyze the size, position and orientation of hip replacement implants and place them precisely where they need to be for the best results.

Remember, motion is medicine, so be sure to stay active despite COVID concerns.

You can find lots more information about COVID-19 best practices on the Rhode Island Department of Health website.

Michael Mason, DO, is a board-certified orthopedic surgeon. He sees patients at Newport Orthopedics, a Lifespan Physician Group practice. Newport Hospital provides this monthly column for The Daily News.

Follow this link:
HEALTH MATTERS: Exercise benefits in the time of COVID-19 - newportri.com

Read More...

Researchers find method to regrow cartilage in the joints – Stanford Medical Center Report

Monday, August 17th, 2020

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, said Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon Matthew Murphy, PhD, a visiting researcher at Stanford who is now at the University of Manchester. I never felt anyone really understood how microfracture really worked, Murphy said. I realized the only way to understand the process was to look at what stem cells are doing after microfracture. Murphy is the lead author on the paper. Chan and Longaker are co-senior authors.

For a long time, Chan said, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage? The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan said. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says. Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

Longaker points out that one advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA. BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, Longaker said. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain. The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker said. You dont wait for damage to accumulate you go in periodically and use this technique to boost your articular cartilage before you have a problem.

Longaker is the Deane P. and Louise Mitchell Professor in the School of Medicine and co-director of the Institute for Stem Cell Biology and Regenerative Medicine. Chan is a member of the Institute for Stem Cell Biology and Regenerative Medicine and Stanford Immunology.

Other Stanford scientist taking part in the research were professor of pathology Irving Weissman, MD, the Virginia and D. K. Ludwig Professor in Clinical Investigation in Cancer Research; professor of surgery Stuart B. Goodman, MD, the Robert L. and Mary Ellenburg Professor in Surgery; associate professor of orthopaedic surgery Fan Yang, PhD; professor of surgery Derrick C. Wan, MD; instructor in orthopaedic surgery Xinming Tong, PhD; postdoctoral research fellow Thomas H. Ambrosi, PhD; visiting postdoctoral scholar Liming Zhao, MD; life science research professionals Lauren S. Koepke and Holly Steininger; MD/PhD student Gunsagar S. Gulati, PhD; graduate student Malachia Y. Hoover; former student Owen Marecic; former medical student Yuting Wang, MD; and scanning probe microscopy laboratory manager Marcin P. Walkiewicz, PhD.

The research was supported by the National Institutes of Health (grants R00AG049958, R01 DE027323, R56 DE025597, R01 DE026730, R01 DE021683, R21 DE024230, U01HL099776, U24DE026914, R21 DE019274, NIGMS K08GM109105, NIH R01GM123069 and NIH1R01AR071379), the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research and the Arthritis National Research Foundation.

The rest is here:
Researchers find method to regrow cartilage in the joints - Stanford Medical Center Report

Read More...

Living with arthritis? 5 easy Pilates moves that can help relieve joint pain – Starts at 60

Monday, August 17th, 2020

So with the help of Clapham, weve rounded up the five best Pilates moves to help relieve joint pain. She recommends incorporating these moves into your daily routine at least three times a week, however, Clapham cautions that you should speak with your doctor before starting a new exercise program.

Clapham says the cat-cow pose is a stretch and release exercise thats wonderful for the lower back and thoracic spine. This move is performed on your hands and knees. To get started, round your spine up towards the ceiling, and keep your gaze between your legs. This is your cat-like shape. Then, arch your back, let your belly relax and lift your head up. This is your cow-like shape.

Clapham says the pike is an effective exercise that can help loosen stiff joints in the neck, shoulders, back, hips, knees and ankles. To get started, Clapham says to start on your hands and knees. Lift your knees off the floor and place your head between your arms with your gaze between your legs. Using your upper body, push the tops of your thighs back and stretch your heels down, creating an inverted V shape with your body. Try to straighten your legs as much as possible without locking your knees.

For those less flexible you can bend your legs on the inhale and straighten them on the exhale and repeat, Clapham advises.

This is a weight-bearing strength exercise that targets your core, glutes and hamstrings, Clapham says, adding: The quadricep is beneficial for those with back pain as it improves your core muscles and [helps] stabilise your spine.

She says to start on your hands and knees, keeping your knees hip-width apart. Then lift one arm in front of you and the opposite leg behind you. Hold this for a few seconds and then repeat on the alternate arm and leg.

Clapham says horse kicks are great for those with hip pain as it loosens the hip joint and strengthens the muscles surrounding the hip. To get started, start on your hands and knees, keeping your knees hip-width apart. Using a kicking motion, lift one leg off the ground, keeping the knee bent at a 90-degree angle and the foot flexed. Lower the leg and then switch legs.

Double leg lifts are a fantastic way to improve your posture, create a stronger core and alleviate back pain, Clapham explains.

Begin by lying on your side with your legs slightly bent, then use your arms to support yourself up. Slowly lift both legs up off the floor before lowering them back down again without touching the floor.

IMPORTANT LEGAL INFO This article is of a general nature and FYI only, because it doesnt take into account your personal health requirements or existing medical conditions. That means its not personalised health advice and shouldnt be relied upon as if it is. Before making a health-related decision, you should work out if the info is appropriate for your situation and get professional medical advice.

Excerpt from:
Living with arthritis? 5 easy Pilates moves that can help relieve joint pain - Starts at 60

Read More...

Best supplement for arthritis: The 28p natural remedy that could ease your joint pain – Express

Monday, August 17th, 2020

Nobody enjoys needless pain it's not like you're getting any benefit from aching joints. Put a stop to it today by popping a simple pill.

Arthritis is a common condition, attests the National Health Service (NHS), that causes pain and inflammation in a joint.

Apparently, the disease affects "more than 10 million people" in the UK.

The consumption of a natural remedy - only 28p could help to reduce symptoms of arthritis.

These are said to block the production of inflammatory chemicals, such as "TNF-alpha", making them useful to ease joint pain.

The Cellular and Molecular Biology Division, in India, conducted a placebo- controlled study into the effects of Boswellia on joint pain.

The study enrolled 75 volunteers who had been diagnosed with osteoarthritis - a type of arthritis.

Each participant was given either 100mg or 250mg of Boswellia extract, or a daily placebo.

The trail went on for three months, and the participants were evaluated for pain and physical functions at different intervals.

On day 0, day seven, day 30, day 60, and day 90, the participants' levels of pain were documented.

In addition to this, the cartilage degrading enzyme, matrix metalloproteinase-3, was evaluated in patients' synovial fluids.

At the end of the study, the researchers noted that both doses of Boswellia extract (100mg or 250mg) showed "clinically and statistically significant improvements in pain scores and physical function scores".

The higher dosage of Boswellia extract saw a "significant improvement in pain score and functional ability" in seven days after starting treatment.

In line with these findings, the 250mg of Boswellia extract also showed a reduction in synovial fluid matrix metalloproteinase-3 in seven days.

Natures Way Boswellia Extract provides 307mg in each supplement pill, which suggests it would be an effective pain reliever.

The active ingredient is Boswellia serrata Tree Resin, which is native to India, North Africa and the Middle East.

The resin is obtained by peeling away strips of bark and then harvesting the gum that oozes out to harden over the wound.

This isn't a new development, in fact it's been used in Chinese medicine for years.

Mr Wakeman added: "[Boswellia] has the added benefit of low side effects.

"For those patients seeking an alternative to paracetamol and ibuprofen for relief of joint pain especially, it is worth considering Boswellia.

See the original post:
Best supplement for arthritis: The 28p natural remedy that could ease your joint pain - Express

Read More...

Treat Arthritis and Joint Pain with Swami Ramdev’s effective yoga asanas – India TV News

Monday, August 17th, 2020

Arthritis and joint pain become very common as one age. From feeling the pain while sitting or standing to swellings in the joint, people are increasingly suffering from joint pain. Neck, back, knee, wrists pain have become overtly common during the lockdown because of long working hours. Sitting in one position for work for long hours is also a reason for people suffering from arthritis.

Arthritis isof two types. One is osteoarthritis that results from the breakdown of the cartilage and the other is rheumatoid arthritis which is caused by weak immunity. The reason behind all this is the lack of exercise and a bad lifestyle. Swami Ramdev, in a special show on India TV, shares effective yoga asanas and pranayamas that are effective in treating Arthritis and joint pain.

Swami Ramdev claims that sukshma vyayamas are very effective in keeping the joints flexible and protects the body from arthritis. He suggests doing yoga asanas like tadasanas, chakki asana, sthit konasana, makrasana, bhujangasana, markatasana, setubandh asana and uttanpadasana to treat neck, back and knee pain.

Swami Ramdev says that pranayamas maintain proper blood circulation in the body which helps keep our organs healthy. He suggests starting the day with surya namaskar and then perform pranayamas like kapalbhati, anulom vilom, and bhastrika for effective results. He says that one can do kapalbhati for half an hour to one hour. He also suggests increasing the number of pranayamas every week as your body gets used to it.

MoreBollywood storiesandpicture galleries

For all latestnewsandupdates,staytuned toourFacebookpage

Fight against Coronavirus: Full coverage

View original post here:
Treat Arthritis and Joint Pain with Swami Ramdev's effective yoga asanas - India TV News

Read More...

TNF and Non-TNF Inhibitors Display Comparable Effectiveness for Rheumatoid Arthritis Treatment – Rheumatology Advisor

Monday, August 17th, 2020

Tumor necrosis factor inhibitors (TNFis) have comparable effectiveness to non-TNFis in the treatment of rheumatoid arthritis (RA), according to study data published in Annals of the Rheumatic Diseases.

Investigators extracted data from the Consortium of Rheumatology Researchers of North America RA Registry, a large healthcare database of patients with RA in the United States. Adult patients with clinician-diagnosed RA and a Clinical Disease Activity Index (CDAI) >2.8 were eligible for inclusion in the study. Patients who were initiated with a first-line TNFi or non-TNFi between 2001 and 2018 were enrolled. Patients with prior exposure to a biologic or targeted synthetic DMARD were excluded from the study. Baseline clinical and demographic characteristics were collected before treatment initiation. The primary outcome was change in CDAI at 1 year after initiation of TNFi or non-TNFi. Low disease activity was defined as CDAI 10; remission was defined as CDAI 2.8. Secondary end points included various patient-reported outcomes, such as quality of life, quality of sleep, fatigue, and morning stiffness. Groups were propensity score-matched at baseline. Random effect regression models were used to compare outcome measures between the TNFi and non-TNFi treatment groups.

The study cohort included 4816 individuals, among whom 4186 were with initiated a TNFi and 630 with a non-TNFi. The mean age of patients in the TNFi and non-TNFi groups were 56.912.7 years and 62.713.0 years, respectively. A majority of the TNFi and non-TNFi groups were women (76.5% and 79.8%, respectively).

Overall, both groups had significant improvements in RA symptoms and patient-reported quality of life. At 1 year, similar proportions of the TNFi and non-TNFi groups achieved low disease activity (39.9% and 41.6%, respectively; P =.87) and remission (17.6% vs 16.3%; P =.26). Both groups also had comparable improvements in mean changes in CDAI (P =.16), Health Assessment Questionnaire scores (P =.07), and patient-reported morning stiffness (P =.29) and fatigue (P =.42). After propensity matching, the TNFi vs non-TNFi groups had lower incidence of anemia (19.04 vs 24.01 cases per 100 person-years, respectively; P =.03). However, the 2 groups did not significantly differ on other outcomes.

Results indicated that both TNFi and non-TNFi treatment may be appropriate after the failure to respond to csDMARDs.

The findings of no significant differences in outcomes between first-line TNF and first-line non-TNF groups support RA guidelines which recommend [individualized] care based on clinical judgement and consideration of patient preferences, the investigators concluded.

Disclosures: This study was supported by Corrona, LLC, and the analysis was supported by Regeneron Pharmaceuticals, Inc, and Sanofi.

Pappas DA, St John G, Etzel CJ, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. Published online July 21, 2020. doi:10.1136/annrheumdis-2020-217209

See original here:
TNF and Non-TNF Inhibitors Display Comparable Effectiveness for Rheumatoid Arthritis Treatment - Rheumatology Advisor

Read More...

Rheumatoid arthritis symptoms: The warning sign on your skin to watch out for – Express

Monday, August 17th, 2020

It adds: "Controlling the rash or ulcers requires controlling the underlying inflammation."

According to the NHS, treatments can help reduce inflammation in the joints, relieve pain, prevent or slow down joint damage, reduce disability and enable you to be as active as possible.

"If you've been diagnosed with rheumatoid arthritis, you'll usually be offered a combination of DMARD tablets as part of your initial treatment," explains the health body.

These medicines ease the symptoms of the condition and slow down its progression.

It's also important to ensure your overall diet is still healthy and balanced.

"A Mediterranean-style diet, which is based on vegetables, fruits, legumes, nuts, beans, cereals, grains, fish and unsaturated fats such as olive oil, is recommended," says the NHS.

There's also some evidence to suggest that taking fish oil supplements may help reduce joint pain and stiffness caused by rheumatoid arthritis.

It is worth noting that some people with rheumatoid arthritis feel their symptoms get worse after they have eaten certain foods.

"If you think this may be the case for you, it may be useful to try avoiding problematic foods for a few weeks to see if your symptoms improve," advises the NHS.

Read the original:
Rheumatoid arthritis symptoms: The warning sign on your skin to watch out for - Express

Read More...

Page 20«..10..19202122..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick